Home > Newsletters > Drug Industry Daily > AstraZeneca, Ardelyx to Collaborate on Novel NHE3-Inhibitor Drugs
Drug Industry Daily
Oct. 9, 2012 | Vol. 11 No. 198
AstraZeneca, Ardelyx to Collaborate on Novel NHE3-Inhibitor Drugs
AstraZeneca (AZ) has agreed to help shepherd Ardelyx’s NHE3-inhibitor program and primary Phase II compound to commercialization, promising to provide the California startup with as much as $272.5 million if new drugs are developed for certain bowel, kidney and renal disorders.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.